Sanofi Pasteur receives BARDA funding to develop Zika vaccine

Pharmaceutical Company Product News

Sanofi Pasteur has announced that the US government is to provide the company with funding to aid the development of a Zika vaccine.

The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services has agreed to provide $43.2 million (33.36 million pounds) to support this work.

“Sanofi Pasteur has received funding of $43.2 million from the US Biomedical Advanced Research and Development Authority to accelerate the development of a Zika vaccine.“

The money will be used to fund the phase II development and manufacturing of the vaccine, the production of which Sanofi Pasteur commenced in February, shortly after the World Health Organization declared a public health emergency.

It will also help to accelerate the characterisation of the vaccine product, as well as supporting the optimisation of the upstream process to improve production yields.

David Loew, Sanofi executive vice-president and head of Sanofi Pasteur, said: "Based on this collaboration, we can bring together resources and expertise which are essential in fighting this public health concern."

Sanofi Pasteur is creating the vaccine as part of a cooperative research and development agreement with the Walter Reed Army Institute of Research.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags